Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINUS: Ultrasound-guided meniscal wall betamethasone infiltration for degenerative meniscal pain
2023-510079-74-00Phase 3Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of betamethasone dipropionate + betamethasone sodium phosphate in meniscal tear and knee arthralgia (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Change in meniscal pain VAS at 1 month. Planned start Jul 2024; status: authorised.
02
Drugs
betamethasone dipropionate + betamethasone sodium phosphate
03
Conditions
meniscal tearknee arthralgia
Beyond the preview
Go deeper on 2023-510079-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510079-74-00.